Stability and Predictability of Motor Symptom Control in Patients with Advanced Parkinson's Disease (aPD) Receiving Continuous Subcutaneous Foslevodopa/Foscarbidopa (LDP/CDP)

被引：0
|
作者：
Pahwa, R.
Malaty, I.
Soileau, M.
Fung, V.
Garcia, D. Santos
Carroll, C.
Henriksen, T.
Epstein, A.
Yan, C.
Alobaidi, A.
Shewale, A.
Spiegel, A.
Facheris, M.
Shah, M.
Kukreja, P.
Zamudio, J.
Chaudhuri, K.
机构：
来源：
MOVEMENT DISORDERS | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
105
引用
收藏
页码：S44 / S45
页数：2
相关论文
共 50 条
  • [41] The PREPARED Study: An Assessment of Symptom Control in Patients with Advanced Parkinson's Disease Receiving Treatment with Adjunctive Ropinirole Prolonged Release or Ropinirole Immediate Release
    Stocchi, Fabrizio
    Giorgi, Luigi
    Hunter, Brian
    Schapira, Anthony
    NEUROLOGY, 2009, 72 (11) : A413 - A413
  • [42] Overview of Phase 3 Trials of Continuous Subcutaneous Apomorphine Infusion for Parkinson's disease (PD) Patients with Motor Fluctuations
    Pahwa, R.
    van Laar, T.
    Dashtipour, K.
    Ceresoli-Borroni, G.
    MOVEMENT DISORDERS, 2024, 39 : S349 - S349
  • [43] Decrease in UPDRS motor scores following intermittent subcutaneous apomorphine for 6 months in patients with advanced Parkinson's disease
    Trosch, DM
    MOVEMENT DISORDERS, 2004, 19 : S217 - S217
  • [44] Symptom control in patients with advanced Parkinson's disease: Ropinirole prolonged release versus ropinirole immediate release
    Stocchi, F.
    Giorgi, L.
    Hunter, B.
    Schapira, A. H. N.
    MOVEMENT DISORDERS, 2009, 24 : S281 - S281
  • [45] Assessment of dose response and symptom control with ropinirole prolonged release in patients with advanced Parkinson's disease (PD)
    Stocchi, F.
    Hunter, B.
    Giorgi, L.
    Hauser, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 : 554 - 554
  • [46] Assessing the Safety and Tolerability of ABBV-951 (Foscarbidopa/Foslevodopa) in Advanced Parkinson's Disease Patients During a 52-Week Phase 3 Study: Study Design and Updated Patient Baseline Characteristics
    Facheris, M.
    Streit, J.
    Jia, J.
    Standaert, D.
    MOVEMENT DISORDERS, 2020, 35 : S394 - S394
  • [47] Retrospective comparison of the efficacy and costs of STN-DBS and continuous subcutaneous infusion of apomorphine in patients with advanced Parkinson's disease
    van Laar, T
    Werdelin, L
    MOVEMENT DISORDERS, 2004, 19 : S310 - S310
  • [48] Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study (Aug, 10.1007/s40120-023-00533-1, 2023)
    Aldred, Jason
    Freire-Alvarez, Eric
    Amelin, Alexander V.
    Antonini, Angelo
    Bergmans, Bruno
    Bergquist, Filip
    Bouchard, Manon
    Budur, Kumar
    Carroll, Camille
    Chaudhuri, K. Ray
    Criswell, Susan R.
    Danielsen, Erik H.
    Gandor, Florin
    Jia, Jia
    Kimber, Thomas E.
    Mochizuki, Hideki
    Robieson, Weining Z.
    Spiegel, Amy M.
    Standaert, David G.
    Talapala, Saritha
    Facheris, Maurizio F.
    Fung, Victor S. C.
    NEUROLOGY AND THERAPY, 2023,
  • [49] Continuous subcutaneous apomorphine infusion: An effective and cognitive well-tolerated solution for untreatable motor fluctuations in patients with Parkinson's disease
    Stefani, CV
    Drapier, S
    Peron, J
    Sauleau, P
    Biseul, I
    Verin, M
    MOVEMENT DISORDERS, 2005, 20 : S79 - S79
  • [50] Continuous subcutaneous apomorphine infusion: An effective and cognitive well-tolerated solution for untreatable motor fluctuations in patients with Parkinson's disease
    Stefani, CV
    Drapier, S
    Peron, J
    Sauleau, P
    Verin, M
    NEUROLOGY, 2005, 64 (06) : A396 - A396
12345